Metraipolis › archive › dc_fc1ecd5eccc1

Comparative Real-World Outcomes of OnabotulinumtoxinA and CGRP Monoclonal Antibodies in Chronic Migraine — Europe PMC PMID:42452425

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42452425
DOI
10.3390/jcm15134963
License (as archived)
solo-consultazione
Archived
2026-10-19T01:44:56.014Z
SHA-256 of the archived text
9c10319268b6fa5c667cf6da78a8b7abe6b6cc307ea5af1704c153e149ffef68
Stable URL of this page
https://metraipolis.com/documento/dc_fc1ecd5eccc1

How to cite

Comparative Real-World Outcomes of OnabotulinumtoxinA and CGRP Monoclonal Antibodies in Chronic Migraine — Europe PMC PMID:42452425 — Europe PMC (en), https://europepmc.org/article/MED/42452425 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_fc1ecd5eccc1 (Metraipolis archive dc_fc1ecd5eccc1, sha256 9c10319268b6fa5c667cf6da78a8b7abe6b6cc307ea5af1704c153e149ffef68)
BibTeX
@misc{dcfc1ecd5eccc1,
  title = {Comparative Real-World Outcomes of OnabotulinumtoxinA and CGRP Monoclonal Antibodies in Chronic Migraine — Europe PMC PMID:42452425},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42452425},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_fc1ecd5eccc1; sha256 9c10319268b6fa5c667cf6da78a8b7abe6b6cc307ea5af1704c153e149ffef68},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42452425. Agents can read the archived copy with the MCP tool read_document.